Drug Profile
BOLD 100
Alternative Names: BOLD 100; IT-139; KP 1339; NKP-1339Latest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator Medical University of Vienna; Queens University Belfast; University of Vienna
- Developer Bold Therapeutics; Georgetown University; Hana Pharm; Intezyne; University of Ottawa
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA inhibitors; Molecular chaperone GRP78 protein inhibitors; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Pancreatic cancer
- Preclinical COVID 2019 infections; Triple negative breast cancer
- No development reported Solid tumours
Most Recent Events
- 22 Jan 2024 Efficacy and adverse events data from a phase I/II trial in Colorectal cancer released by Bold Therapeutics
- 14 Sep 2023 Bold Therapeutics expects accelerated approval of BOLD 100 in 2027
- 14 Sep 2023 Bold Therapeutics plans multinational pivotal phase-III randomized trial for colorectal cancer in 2024